New Hampshire School’s Medication Law

NEW HAMPSHIRE TITLE XV EDUCATION CHAPTER 200 HEALTH AND SANITATION Use of Asthma Medications by Pupils 200:46 Possession and Self-Administration of Asthma Inhalers Permitted A pupil may possess and use a metered dose inhaler or a dry powder inhaler to alleviate asthmatic symptoms, or before exercise to prevent the onset of asthmatic symptoms, if the following conditions are satisfied: I. The pupil has the written approval of the pupil’s physician and, if the pupil is a minor, the written approval of the parent or guardian. The school shall obtain the following information from the pupil’s physician: (a) The pupil’s name. (b) The name and signature of the licensed prescriber and business and emergency numbers. (c) The name, route, and dosage of medication. (d) The frequency and time of medication administration or assistance. (e) The date of the order. (f) A diagnosis and any other medical conditions requiring medications, if not a violation of confidentiality or if not contrary to the request of the parent or guardian to keep confidential. (g) Specific recommendations for administration. (h) Any special side effects, contraindications, and adverse reactions to be observed. (i) At least one emergency telephone number for contacting the parent or guardian. (j) The name of each required medication. II. The school principal or, if a school nurse is assigned to the pupil’s school building, the school nurse shall receive copies of the written approvals required by paragraph I. III. The pupil’s parent or guardian shall submit written verification from the physician confirming that the pupil has the knowledge and skills to safely possess and use an asthma inhaler in a school setting. IV. If the conditions provided in this section are satisfied, the pupil may possess and use the inhaler at school or at any school sponsored activity, event, or program. V. In this section, “physician” includes any physician or health practitioner with the authority to write prescriptions. Source. 2003, 51:3, eff. Aug. 15, 2003. Pupil Use of Epinephrine Auto-Injectors Section 200:42 200:42 Possession and Use of Epinephrine Auto-Injectors Permitted. – A pupil with severe, potentially life-threatening allergies may possess and self-administer an epinephrine auto-injector if the following conditions are satisfied: I. The pupil has the written approval of the pupil’s physician and, if the pupil is a minor, the written approval of the parent or guardian. The school shall obtain the following information from the pupil’s physician: (a) The pupil’s name. (b) The name and signature of the licensed prescriber and business and emergency numbers. (c) The name, route, and dosage of medication. (d) The frequency and time of medication administration or assistance. (e) The date of the order. (f) A diagnosis and any other medical conditions requiring medications, if not a violation of confidentiality or if not contrary to the request of the parent or guardian to keep confidential. (g) Specific recommendations for administration. (h) Any special side effects, contraindications, and adverse reactions to be observed. (i) The name of each required medication. (j) Any severe adverse reactions that may occur to another pupil, for whom the epinephrine auto-injector is not prescribed, should such a pupil receive a dose of the medication. II. The school principal or, if a school nurse is assigned to the pupil’s school building, the school nurse shall receive copies of the written approvals required by paragraph I. III. The pupil’s parent or guardian shall submit written verification from the physician confirming that the pupil has the knowledge and skills to safely possess and use an epinephrine auto-injector in a school setting. IV. If the conditions provided in this section are satisfied, the pupil may possess and use the epinephrine auto-injector at school or at any school-sponsored activity, event, or program. V. In this section, “physician” includes any physician or health practitioner with the authority to write prescriptions. Source. 2003, 50:1, eff. Aug. 15, 2003. Safety Regulations Section 485-A:25-b 485-A:25-b Possession and Use of Epinephrine Auto-Injectors at Recreation Camps. – A recreation camp shall permit a child with severe, potentially life-threatening allergies to possess and use an epinephrine auto-injector, if the following conditions are satisfied: I. The child has the written approval of the child’s physician and the written approval of the parent or guardian. The camp shall obtain the following information from the child’s physician: (a) The child’s name. (b) The name and signature of the licensed prescriber and business and emergency numbers. (c) The name, route, and dosage of medication. (d) The frequency and time of medication administration or assistance. (e) The date of the order. (f) A diagnosis and any other medical conditions requiring medications, if not a violation of confidentiality or if not contrary to the request of the parent or guardian to keep confidential. (g) Specific recommendations for administration. (h) Any special side effects, contraindications, and adverse reactions to be observed. (i) The name of each required medication. (j) Any severe adverse reactions that may occur to another child, for whom the epinephrine auto-injector is not prescribed, should such a pupil receive a dose of the medication. II. The recreational camp administrator or, if a nurse is assigned to the camp, the nurse shall receive copies of the written approvals required by paragraph I. III. The child’s parent or guardian shall submit written verification from the physician confirming that the child has the knowledge and skills to safely possess and use an epinephrine auto-injector in a camp setting. IV. If the conditions provided in this section are satisfied, the child may possess and use the epinephrine auto-injector at the camp or at any camp-sponsored activity, event, or program. V. In this section, “physician” means any physician or health practitioner with the authority to write prescriptions. Source. 2003, 50:2, eff. Aug. 15, 2003.